Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors.

By N. Lindor, L. Burgart, Olga N Leontovich, R. Goldberg, J. Cunningham, D. Sargent, C. Walsh-Vockley, G. Petersen, M. Walsh, B. Leggett and 8 more. Journal of Clinical Oncology, 2002

831 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/81f4a9c69fc335603c1f4fe3ab44a73d492f2446

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. René Bernards
2. Joe W. Gray
3. Jeffrey S. Morris
4. Louis Vermeulen
5. E. Fessler
6. J. Medema
7. D. Hanahan
8. Rakesh K. Jain

In Pathology and Forensic Medicine

1. Joe W. Gray
2. D. Hanahan

Citations in the corpus

• The Consensus Molecular Subtypes of Colorectal Cancer (2015, methodology): “is supported by grants from the Dutch Cancer Society (UVA2011-4969, UVA2014-7245), Worldwide Cancer Research (14-1164), the Maag Lever Darm Stichting (MLDS-CDG 14-03) and the European Research Council (ERG-StG 638193).”
• Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. (2004, background): “Interestingly, only 2% of MSI-H tumors express both proteins (14); the clinical significance of this observation has not yet been determined.”
• Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications (2009, background): “3%) screening tool, but that some MSI-H tumors will be missed if only IHC is performed (69).”
• Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies (2014, methodology): “3%) and specific (100%) method for screening for dMMR.(27) Venderbosch et al.”